The drug-eluting stent (DES) market focuses on coronary stents coated with medications that are slowly released to prevent the re-narrowing of arteries after angioplasty. These stents combine mechanical support to keep blood vessels open with localized drug delivery to reduce restenosis and the need for repeat procedures. Market growth is driven by the rising global incidence of cardiovascular diseases, increasing adoption of minimally invasive procedures, an aging population, and continuous improvements in stent design and drug coatings. New-generation DES feature thinner struts, biodegradable polymers, and improved biocompatibility for better patient outcomes. Hospitals and specialty cardiac centers are the primary end users. North America currently leads the market thanks to advanced healthcare infrastructure, high rates of coronary interventions, and rapid approval of innovative products, while Asia-Pacific is expected to see the fastest growth due to expanding healthcare access, a growing patient base, and rising lifestyle-related heart conditions. Key challenges include high procedure costs, the risk of late thrombosis, and strict regulatory requirements for new stent technologies.
The global drug eluting stent (DES) market size was valued at USD 5.71 billion in 2018 and is projected to reach USD 13.52 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period. North America dominated the drug eluting stent market with a 30.82% share in 2018, driven by advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and strong adoption of innovative stent technologies.
The DES market growth is being driven by several interlinked factors: rising prevalence of cardiovascular diseases (CVDs), increasing cases of coronary artery disease (CAD), arterial blockage concerns, higher occurrence of peripheral arterial disease (PAD), and growing healthcare expenditure globally.
Technological advancement also plays a major role: introduction of new designs, improved stent delivery systems, development of bioresorbable polymer coatings, ultrathin stent struts, and enhanced scaffold materials reduce risks such as restenosis and thrombosis. These innovations are pushing adoption rates higher.